BioCentury
ARTICLE | Clinical News

GNbAC1: Phase IIb started

January 11, 2016 8:00 AM UTC

GeNeuro began the placebo-controlled, European Phase IIb CHANGE-MS trial to evaluate GNbAC1 in 260 patients. In 2014, GeNeuro granted Servier (Neuilly-sur-Seine, France) an option to license exclusiv...